FNCH
Finch Therapeutics Group, Inc.13.50
+0.06+0.45%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
21.68MP/E (TTM)
-Basic EPS (TTM)
-8.80Dividend Yield
0%Recent Filings
8-K
Finch delists from Nasdaq
Finch Therapeutics Group initiated delisting its common stock from Nasdaq on October 17, 2024, after suspension on May 28 due to a 'public shell' status and compliance failures like low public float value. The board aims to slash SEC reporting costs and management burdens under Sarbanes-Oxley. Form 25 filing is set for October 31, with delisting effective 10 days later and full deregistration following. Trading persists on OTC markets, yet continuity isn't assured.
10-Q
Q2 FY2024 results
Finch Therapeutics narrowed its Q2 net loss to $4.8 million from $7.0 million a year earlier, while the six-month figure hit $8.7 million versus $69.3 million last year, thanks to the 2023 Strategic Reprioritization that slashed R&D and personnel costs. Operating expenses dropped to $6.1 million in the quarter from $9.9 million, driven by lower legal fees and facilities outlays, with no revenue as the company eyes IP licensing. Cash and equivalents stood at $16.0 million at quarter-end, down from $25.1 million six months prior, funding operations into 2025 amid ongoing litigation. A jury verdict on August 9 awarded $25.8 million in damages against Rebiotix for willful infringement of microbiome patents, though appeals loom. Litigation costs remain high. Nasdaq delisting to OTC markets curbs liquidity.
8-K
Jury rules for Finch in patent case
Finch Therapeutics Group scored a jury win on August 9, 2024, in its Delaware patent infringement suit against Ferring Pharmaceuticals, with willful infringement found on key claims for microbiome therapy patents. The verdict nets Finch and the University of Minnesota $25.0 million upfront plus $0.815 million in running royalties for Rebyota sales through trial. Jury invalidates one claim each from two Finch patents. Ferring plans post-trial motions and appeal.
8-K
Nasdaq delisting confirmed for Finch
Finch Therapeutics Group faces Nasdaq delisting after a panel upheld the determination that it's a public shell without an operating business, stemming from a February 2024 notice. Trading of its common stock suspends May 28, 2024, with removal via Form 25-NSE no sooner than 45 days later, shifting to the OTC market. No guarantees exist for prompt or sustained OTC trading. This strips institutional access, shrinking liquidity.
8-K
Nasdaq delisting risk escalates
Finch Therapeutics Group failed to meet Nasdaq's $5.0 million minimum market value of publicly held shares by the May 13, 2024 deadline, prompting an additional delisting determination on May 14. The company, already appealing a 'public shell' label from an April 23 hearing, requested transfer to the Nasdaq Capital Market on May 15. Delisting looms if appeals fail. Compliance remains uncertain.
IPO
Employees
Sector
Industry
CMND
Clearmind Medicine Inc.
2.62-0.10
ENTO
Entero Therapeutics Inc.
2.99+0.15
FBLG
FibroBiologics, Inc.
0.24-0.02
GANX
Gain Therapeutics, Inc.
3.86-0.09
GLTO
Galecto, Inc.
30.00-1.60
IMA
ImageneBio, Inc.
6.25+0.08
NKTR
Nektar Therapeutics
49.16-4.14
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
SYBX
Synlogic, Inc.
1.06+0.01
SYRE
Spyre Therapeutics, Inc.
32.97-0.37